Study: Microdosing LSD for 1 month was followed by improved mood, productivity
Might microdosing LSD and psilocybin be a safe, effective way to treat depression and other disorders?
- A recent study collected the self-reports of more than 1,000 people who microdosed LSD or psilocybin regularly for about a month.
- The results showed that most people experienced more positive moods, less depression and increased productivity.
- These results are preliminary, and microdosing remains an under-researched area.
Microdosing psychedelic drugs on a regular basis might be a safe way to improve your mood and productivity, according to a new study published in the Journal of Psychoactive Drugs.
Microdosing is a practice in which you take a very small or "sub-perceptual" dose of drugs in order to reap the benefits of the drug without experiencing too much of its consciousness-altering effects. In the recent study, researchers collected reports from more than 1,000 participants in 59 countries, most of whom microdosed once every three days for a month. (The researchers defined microdoses as between 7 to 13 micrograms for LSD; 0.1 to 0.4 grams for dried psilocybin mushrooms.)
This microdosing regimen was followed by "improvements in negative moods, especially depression, and increases in positive moods. Increased energy, improved work effectiveness, and improved health habits were observed in clinical and nonclinical populations," the researchers wrote. One participant reported: "Feeling productive, able to focus on what I choose, enjoying relationships, good energy, and not recalling that I took anything."
The preliminary results suggest that "microdosing has none of the classic exciting effects of psychedelics, is safer, and many people all over the world report taking these low doses to be beneficial," study author James Fadiman, who's been researching psychedelics for decades, told PsyPost.
Still, the researchers cautioned against attaching clinical significance to their statistically significant results, which came from self-reports.
"While statistical significance can give us information about a low-level change over a large population — for example, improving one point on the Beck Depression Inventory — this may mean little to people suffering from depression," they wrote. "However, many participants informed us that they found microdosing to be an effective antidepressant, or replacement for their antidepressants. For example, a 70-year-old man writes: 'For the first time in 31 years, I am off antidepressants' and includes descriptions of moments when his emotional range has clearly been expanded."
The researchers also mentioned that the positive results could be explained by the placebo effect. That possibility didn't matter to at least one participant, who wrote: "I don't care if it's a placebo or not, all I know is I haven't felt this good in decades."
Other research on microdosing
Microdosing is far from a new idea. Decades ago, Albert Hoffman, the first scientist to synthesize and ingest LSD, suggested that low doses of LSD might be a suitable replacement for Ritalin. However, like psychedelics in general, scientists still have much to learn about how taking regular small doses of psychedelic drugs affects the body over time. Fortunately, there have been some illuminating studies and reports in recent years that suggest microdosing LSD or psilocybin has the potential to:
- Boost divergent and convergent thinking, both of which are considered fundamental to creativity. (Note: The 2018 study that observed these effects also found that microdosing seemed to have no effect on fluid intelligence.)
- Alleviate anxiety and depression.
- Increase productivity, at least as reported by many in Silicon Valley who've turned to microdosing as sort of the ultimate productivity hack.
Of course, if you're interested in microdosing or experimenting with psychedelic drugs, you should approach them at your own risk. After all, they're not for everybody, as Fadiman told PsyPost.
"People whose major symptom is anxiety should not microdose. Although there are thousands of years of recorded use, there are no contemporary double-blind studies. Inform yourself."
- The Long-Term Effects of Microdosing LSD – Erica Avey – Medium ›
- First ever trials on the effects of microdosing LSD set to begin ... ›
Former president of the ACLU Nadine Strossen discusses whether our society should always defend free speech rights, even for groups who would oppose such rights.
- Former ACLU president Nadine Strossen understands that protecting free speech rights isn't always a straightforward proposition.
- In this video, Strossen describes the reasoning behind why the ACLU defended the free speech rights of neo-Nazis in Skokie, Illinois, 1977.
- The opinions expressed in this video do not necessarily reflect the views of the Charles Koch Foundation, which encourages the expression of diverse viewpoints within a culture of civil discourse and mutual respect.
A new paradigm for machine vision has just been demonstrated.
- Scientists have invented a way for a sheet of glass to perform neural computing.
- The glass uses light patterns to identify images without a computer or power.
- It's image recognition at the speed of light.
A consortium of scientists and engineers have proposed that the U.S. and Mexico build a series of guarded solar, wind, natural gas and desalination facilities along the entirety of the border.
- The proposal was recently presented to several U.S. members of Congress.
- The plan still calls for border security, considering all of the facilities along the border would be guarded and connected by physical barriers.
- It's undoubtedly an expensive and complicated proposal, but the team argues that border regions are ideal spots for wind and solar energy, and that they could use the jobs and fresh water the energy park would create.
"A monkey has been able to control a computer with its brain," Musk said, referring to tests of the device.
- Neuralink seeks to build a brain-machine interface that would connect human brains with computers.
- No tests have been performed in humans, but the company hopes to obtain FDA approval and begin human trials in 2020.
- Musk said the technology essentially provides humans the option of "merging with AI."